Last edition
News about "Nanomi"
Lupin Launches Risperidone Extended-Release Injectable with 180-day CGT Exclusivity in the US
Risperidone Long-Acting Injectable is Lupin’s first product using its proprietary PrecisionSphere technology developed by its subsidiary Nanomi.
Nanomi | 14/11/2025 | By Dineshwori
Lupin Launches Strategic Partnership Programme to Expand Reach of PrecisionSphere
Global pharma major Lupin has launched a strategic partnership programme aimed at expanding the reach of PrecisionSphere – the long-acting injectable (LAI) platform developed by its subsidiary, Nanomi.
Nanomi | 09/10/2025 | By Dineshwori
Lupin Acquires VISUfarma, Strengthens Global Specialty Ophthalmology Business
By integrating VISUfarma’s established commercial operations, Lupin aims to tap into the attractive ophthalmology market.
Nanomi | 30/09/2025 | By Dineshwori
Lupin Secures US FDA Approval for Risperidone Long-Acting Injectable
Lupin has received US FDA approval for its Risperidone extended-release injectable suspension, marking the first product from its Nanomi long-acting injectables platform with 180-day CGT exclusivity.
Nanomi | 03/09/2025 | By Mrinmoy Dey
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy